Middleton & Co. Inc. MA Purchases 525 Shares of Zoetis Inc. $ZTS

Middleton & Co. Inc. MA increased its holdings in Zoetis Inc. (NYSE:ZTS) by 4.0% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 13,498 shares of the company’s stock after buying an additional 525 shares during the period. Middleton & Co. Inc. MA’s holdings in Zoetis were worth $2,105,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in ZTS. Nuveen LLC purchased a new stake in shares of Zoetis in the 1st quarter valued at about $616,375,000. Mackenzie Financial Corp increased its position in shares of Zoetis by 4,158.3% in the first quarter. Mackenzie Financial Corp now owns 1,824,967 shares of the company’s stock worth $300,481,000 after purchasing an additional 1,782,110 shares during the last quarter. Polen Capital Management LLC increased its position in shares of Zoetis by 17.6% in the first quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company’s stock worth $1,448,401,000 after purchasing an additional 1,313,653 shares during the last quarter. Amundi raised its stake in Zoetis by 30.8% in the first quarter. Amundi now owns 3,595,628 shares of the company’s stock valued at $575,691,000 after purchasing an additional 846,909 shares in the last quarter. Finally, OVERSEA CHINESE BANKING Corp Ltd grew its stake in Zoetis by 475.9% in the 1st quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 900,261 shares of the company’s stock worth $148,228,000 after buying an additional 743,926 shares in the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Zoetis Stock Down 0.6%

Shares of Zoetis stock opened at $119.81 on Friday. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05. Zoetis Inc. has a 12-month low of $119.06 and a 12-month high of $181.85. The company has a market cap of $53.10 billion, a P/E ratio of 20.62, a PEG ratio of 2.31 and a beta of 0.90. The company’s fifty day simple moving average is $144.93 and its two-hundred day simple moving average is $152.78.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Tuesday, November 4th. The company reported $1.70 EPS for the quarter, topping the consensus estimate of $1.62 by $0.08. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The business had revenue of $2.40 billion during the quarter, compared to analyst estimates of $2.42 billion. During the same period last year, the business posted $1.58 earnings per share. Zoetis’s quarterly revenue was up .5% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Research analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 2nd. Stockholders of record on Friday, October 31st will be given a $0.50 dividend. The ex-dividend date of this dividend is Friday, October 31st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.7%. Zoetis’s dividend payout ratio is currently 33.67%.

Analysts Set New Price Targets

A number of research analysts recently commented on ZTS shares. Piper Sandler increased their target price on Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a research note on Monday, August 11th. Weiss Ratings reissued a “hold (c-)” rating on shares of Zoetis in a report on Wednesday, October 8th. JPMorgan Chase & Co. cut their target price on Zoetis from $230.00 to $200.00 and set an “overweight” rating for the company in a research note on Wednesday. UBS Group lowered their price target on shares of Zoetis from $158.00 to $141.00 and set a “neutral” rating for the company in a research note on Wednesday. Finally, Leerink Partnrs lowered Zoetis from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 17th. Five research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat.com, Zoetis currently has a consensus rating of “Moderate Buy” and an average target price of $191.00.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.